Claims for Patent: 8,329,680
✉ Email this page to a colleague
Summary for Patent: 8,329,680
Title: | Formulation |
Abstract: | The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1- ,3,5(10)-triene-3,17.beta.-diol, more particularly to a formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-- triene-3,17.beta.-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle. |
Inventor(s): | Evans; John R (Macclesfield, GB), Grundy; Rosalind U (Macclesfield, GB) |
Assignee: | AstraZeneca AB (Sodertalje, SE) |
Application Number: | 12/285,887 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,329,680 |
Patent Claims: |
1. A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in
need of such treatment a formulation comprising: about 50 mgml.sup.-1 of fulvestrant; about 10% w/v of ethanol; about 10% w/v of benzyl alcohol; about 15% w/v of benzyl benzoate; and a sufficient amount of castor oil vehicle; wherein the method
achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml.sup.-1 for at least four weeks.
2. The method of claim 1, wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml.sup.-1. 3. The method of claim 1, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer. 4. The method of claim 1, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation. 5. The method of claim 1, wherein the method further comprises once monthly administration of the formulation. 6. The method of claim 2, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer. 7. The method of claim 6, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation. 8. The method of claim 7, wherein the method further comprises once monthly administration of the formulation. 9. A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation consisting essentially of: about 50 mgml.sup.-1 of fulvestrant; about 10% w/v of ethanol; about 10% w/v of benzyl alcohol; about 15% w/v of benzyl benzoate; and wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml.sup.-1 for at least four weeks. 10. The method of claim 9, wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml.sup.-1. 11. The method of claim 9, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer. 12. The method of claim 9, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation. 13. The method of claim 9, wherein the method further comprises once monthly administration of the formulation. 14. The method of claim 10, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer. 15. The method of claim 14, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation. 16. The method of claim 15, wherein the method further comprises once monthly administration of the formulation. 17. The method according to claim 1, wherein the formulation is administered in a divided dose. 18. The method according to claim 8, wherein the formulation is administered in a divided dose. 19. The method according to claim 9, wherein the formulation is administered in a divided dose. 20. The method according to claim 16, wherein the formulation is administered in a divided dose. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.